# Abbott Laboratories (ABT)

Source: https://www.quantisnow.com/company/ABT
Generated: 2026-11-22T20:32:24.493Z

- Ticker: ABT
- Exchange: NYSE
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0000001800
- Website: abbott.com

## About

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, MÃ©niÃ¨re's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.

## Latest ABT news and filings

- 2026-11-19 14:00 UTC [Abbott initiates VOYAGER clinical trial for investigational Encantor™ software-guided balloon-expandable TAVI system to treat aortic stenosis](https://www.quantisnow.com/insight/abbott-initiates-voyager-clinical-trial-for-investigational-encantor-software-guided-balloon-expandable-6800183)
- 2026-11-19 12:25 UTC [Analyst Upgrade] [Abbott Labs upgraded by Leerink Partners with a new price target](https://www.quantisnow.com/insight/abbott-labs-upgraded-by-leerink-partners-with-a-new-price-6799850)
- 2026-11-13 22:59 UTC [SEC Form 8-K] [Abbott Laboratories filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/abbott-laboratories-filed-sec-form-8-k-leadership-update-6793837)
- 2026-11-10 11:08 UTC [New Abbott Panbio™ COVID-19/Flu A&B Self-Test Helps Canadian Families Make Informed Decisions During Respiratory Illness Season](https://www.quantisnow.com/insight/new-abbott-panbio-covid-19flu-ab-self-test-helps-canadian-families-make-6782501)
- 2026-11-06 22:09 UTC [SEC Form 4] [EXECUTIVE VICE PRESIDENT Moreland Mary K sold $406,000 worth of Common shares without par value (3,500 units at $116.00), decreasing direct ownership by 3% to 100,791 units (SEC Form 4)](https://www.quantisnow.com/insight/executive-vice-president-moreland-mary-k-sold-406000-worth-of-6779508)
- 2026-11-04 21:13 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Abbott Laboratories](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-abbott-laboratories-6772680)
- 2026-11-02 14:00 UTC [Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke](https://www.quantisnow.com/insight/late-breaking-one-year-data-show-abbotts-next-generation-amulet-360-device-continues-6766439)
- 2026-11-01 20:45 UTC [Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System](https://www.quantisnow.com/insight/abbotts-tectonic-clinical-trial-demonstrates-strong-30-day-outcomes-and-high-6765787)
- 2026-10-29 13:00 UTC [Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease](https://www.quantisnow.com/insight/abbott-initiates-pivotal-trial-for-cephea-device-an-innovative-treatment-6762915)
- 2026-10-27 11:43 UTC [Analyst Downgrade] [Abbott Labs downgraded by Argus](https://www.quantisnow.com/insight/abbott-labs-downgraded-by-argus-6758509)
- 2026-10-26 13:00 UTC [Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment](https://www.quantisnow.com/insight/abbott-launches-whole-genome-sequencing-oncodetect-molecular-residual-disease-mrd-test-6757244)
- 2026-10-23 13:15 UTC [Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer](https://www.quantisnow.com/insight/abbott-presents-new-esmo-data-showing-30-percent-absolute-improvement-in-6756008)
- 2026-10-21 17:44 UTC [Dividends] [Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold Firm](https://www.quantisnow.com/insight/nasdaq-and-small-caps-lead-three-day-surge-as-crude-6753323)
- 2026-10-21 13:19 UTC [SEC Form 8-K] [SEC Form 8-K filed by Abbott Laboratories](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-abbott-laboratories-6753189)
- 2026-10-21 11:36 UTC [SEC Form 8-K] [SEC Form 8-K filed by Abbott Laboratories](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-abbott-laboratories-6752923)
- 2026-10-21 11:30 UTC [Earnings Date] [Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance](https://www.quantisnow.com/insight/abbott-reports-third-quarter-2026-results-and-reaffirms-full-year-eps-guidance-6752910)
- 2026-10-21 11:25 UTC [Earnings Date] [Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company](https://www.quantisnow.com/insight/abbott-announces-its-intention-to-separate-its-global-nutrition-business-6752877)
- 2026-10-07 13:00 UTC [Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop](https://www.quantisnow.com/insight/abbott-introduces-ensure-max-protein-3-in-1-muscle-support-bringing-the-6739965)
- 2026-10-07 12:44 UTC [Analyst Coverage Initiated] [Barclays initiated coverage on Abbott Labs with a new price target](https://www.quantisnow.com/insight/barclays-initiated-coverage-on-abbott-labs-with-a-new-price-6739883)
- 2026-10-05 13:00 UTC [Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition](https://www.quantisnow.com/insight/abbott-receives-fda-approval-for-new-cardiomems-hf-system-capabilities-6736215)
- 2026-10-02 20:11 UTC [SEC Form 4] [SEC Form 4 filed by Director Stratton John G](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-stratton-john-g-6734472)
- 2026-10-02 20:11 UTC [SEC Form 4] [SEC Form 4 filed by Director Gonzalez Patricia Paola](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-gonzalez-patricia-paola-6734467)
- 2026-10-02 20:10 UTC [SEC Form 4] [SEC Form 4 filed by Director Conroy Kevin T](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-conroy-kevin-t-6734460)
- 2026-10-02 20:10 UTC [SEC Form 4] [SEC Form 4 filed by Director Ahuja Nita](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-ahuja-nita-6734459)
- 2026-10-02 20:10 UTC [SEC Form 4] [SEC Form 4 filed by Director Roman Michael F](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-roman-michael-f-6734441)
- 2026-10-02 12:32 UTC [Analyst Upgrade] [Abbott Labs upgraded by Rothschild & Co Redburn with a new price target](https://www.quantisnow.com/insight/abbott-labs-upgraded-by-rothschild-co-redburn-with-a-new-6733553)
- 2026-09-30 13:00 UTC [Earnings Date] [Abbott hosts conference call for third-quarter earnings](https://www.quantisnow.com/insight/abbott-hosts-conference-call-for-third-quarter-earnings-6730219)
- 2026-09-30 12:00 UTC [Abbott launches SimpleScreen™ CRC blood test, joining Cologuard Plus® in its colorectal cancer screening portfolio](https://www.quantisnow.com/insight/abbott-launches-simplescreen-crc-blood-test-joining-cologuard-plus-in-6730001)
- 2026-09-25 21:21 UTC [SEC Form 4] [Director Conroy Kevin T covered exercise/tax liability with 52,507 units of Common shares without par value, decreasing direct ownership by 39% to 81,230 units (SEC Form 4)](https://www.quantisnow.com/insight/director-conroy-kevin-t-covered-exercisetax-liability-with-52507-units-6726753)
- 2026-09-23 11:00 UTC [Abbott And Berry Street Partner To Expand Personalized Nutrition Support For Consumers Seeking Better Metabolic Health](https://www.quantisnow.com/insight/abbott-and-berry-street-partner-to-expand-personalized-nutrition-support-6723570)
- 2026-09-17 16:43 UTC [Dividends] [Abbott declares 411th consecutive quarterly dividend](https://www.quantisnow.com/insight/abbott-declares-411th-consecutive-quarterly-dividend-6718846)
- 2026-09-15 10:08 UTC [First Canadian Commercial Use of Abbott's Volt™ Pulsed Field Ablation System Advances Minimally Invasive Atrial Fibrillation Care](https://www.quantisnow.com/insight/first-canadian-commercial-use-of-abbotts-volt-pulsed-field-ablation-6715273)
- 2026-09-14 15:52 UTC [Abbott reaches agreement with Department of Justice to resolve claims relating to 2022 infant formula recall](https://www.quantisnow.com/insight/abbott-reaches-agreement-with-department-of-justice-to-resolve-claims-6714175)
- 2026-09-08 12:00 UTC [Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms](https://www.quantisnow.com/insight/abbott-receives-fda-approval-for-its-tactiflex-duo-ablation-catheter-6707572)
- 2026-09-03 22:11 UTC [SEC Form 4] [VICE PRESIDENT AND CONTROLLER Mccoy John A. Jr. covered exercise/tax liability with 52 units of Common shares without par value and sold $2,958 worth of Common shares without par value (27 units at $109.54), decreasing direct ownership by 0.32% to 24,549 units (SEC Form 4)](https://www.quantisnow.com/insight/vice-president-and-controller-mccoy-john-a-jr-covered-exercisetax-6705802)
- 2026-09-03 22:02 UTC [SEC Form 4] [EVP AND CFO Boudreau Philip P covered exercise/tax liability with 388 units of Common shares without par value, decreasing direct ownership by 0.55% to 70,784 units (SEC Form 4)](https://www.quantisnow.com/insight/evp-and-cfo-boudreau-philip-p-covered-exercisetax-liability-with-6705790)
- 2026-08-31 12:00 UTC [Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula](https://www.quantisnow.com/insight/abbott-launches-the-first-and-only-ready-to-feed-liquid-infant-formula-6699172)
- 2026-08-27 21:09 UTC [SEC Form 4] [CHAIRMAN AND CEO Ford Robert B exercised 398,832 units of Common shares without par value at a strike of $54.02 and sold $46,204,798 worth of Common shares without par value (398,832 units at $115.85) (SEC Form 4)](https://www.quantisnow.com/insight/chairman-and-ceo-ford-robert-b-exercised-398832-units-of-6697466)
- 2026-08-27 13:00 UTC [Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke](https://www.quantisnow.com/insight/abbotts-next-generation-amulet-360-device-receives-ce-mark-to-treat-6696632)
- 2026-08-25 18:49 UTC [Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes](https://www.quantisnow.com/insight/abbott-receives-fda-authorization-for-worlds-first-dual-glucose-ketone-sensing-6694068)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ABT
- Earnings history: https://www.quantisnow.com/earnings/ABT
- Dividend history: https://www.quantisnow.com/dividends/ABT
- Insider transactions: https://www.quantisnow.com/insiders/ABT
- Options chain: https://www.quantisnow.com/options/ABT
- SEC 8-K filings only: https://www.quantisnow.com/company/ABT/8-k
- RSS and alerts for ABT: https://www.quantisnow.com/docs/rss-feeds.md
